We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
13/7/2016 10:37 | Total number of shares issued: 208,339,631 Shareholders with >3% of total issued: Software AG-Stiftung 43,545,567 20.90% Cathal Friel 33,077,347 15.88% Joseph Wiley 20,772,895 9.97% Axa Framlington 20,625,000 9.90% Rory Nealon 9,443,031 4.53% Alan Harris 8,869,090 4.26% Pursuant to the AIM Rules, and insofar as the Company is aware, as at 19/04/16, 62.6% of the Company’s AIM securities were not in public hands take into account large holders/ institutions below 3%, means there isn't a lot of free float in PI's hands | currypasty | |
13/7/2016 07:44 | looks like it was the bottom, don't forget it went down on very little volume, so it can go up just as easy. | currypasty | |
12/7/2016 12:59 | Took 40k, I'm not averaging down again till 12p. Lol | currypasty | |
12/7/2016 12:05 | Lol. Got to admire your humour. CURRYPASTY | jacksonpollack | |
12/7/2016 10:58 | perhaps that's the bottom now? Most of todays trades are actually buys | currypasty | |
12/7/2016 08:00 | pap, me too on oxs, 20k down, ouch.. looked like a stitch up too me. Lesson, avoid anything with litigation! | currypasty | |
12/7/2016 06:10 | Remember these two products, bod's? Come on, get out of bed. It's morning time. Imlan® Many people suffer from dry, itching and allergic skin or face trouble with atopic dermatitis and psoriasis that affects daily life. These conditions require special care. The Imlan® products’ regenerative and anti-inflammatory properties have transformed skin care. Betulin is the active ingredient in the Imlan® products and also functions as the stabilizer of the creams and lotions. This eliminates the use of emulsifiers and preservatives that are usually found in skin care products and that are for many a cause of skin irritation. Imlan® is a 100-percent natural skin care line that contains no colorants, fragrances, paraffin or lanolin. Imlan® Creme Pur contains just three ingredients: Betulin, oil and water. Please visit www.imlan.de/en.html for further information. Episalvan® Episalvan® is a prescription pharmaceutical product which accelerates wound healing. It’s approved in Europe for the treatment of partial-thickness wounds (PTWs) in adults. Such wounds are caused by, including burns, STSG donor sites, skin grafting and other dermatological procedures, aesthetic procedures, decubitus (stage II), toxic epidermal necrolysis and radiation and drug side effects. Episalvan® is a topical product which is simply formulated to contain two ingredients, its betulin-based active ingredient and sunflower oil as the only excipient. The absence of further ingredients potentially reduces the likelihood of skin irritation. Episalvan® gel provides a protective cover to the wound and prevents dressings from sticking to the wound, further supporting its pharmacological action to accelerate wound healing. | jacksonpollack | |
12/7/2016 05:59 | Could be a case of too many chefs spoil the broth. Too many bod's spoil the share. They have a marketable and approved, by Europe, product selling in Germany with £1m revenue. Here's a radical idea. Sell it all over Europe. You are allowed, it has been approved. FFS what are all these bod's doing apart from watching the share price sink and milking the dwindling funds? If you have an approved product you go balls out to exploite if to its fullest potential. It ain't rocket science. Here's another idea, bod. Buy some shares in the company to show some faith. Yes, CF bought some many moons ago, but what about the rest. I'm not talking about giving yourselves free shares or warrants. Open your wallets and show some confidence to the market and in the company. | jacksonpollack | |
11/7/2016 15:03 | As far as I can see on the charts of AIM shares, the market has held up very well. As you can see below AIM all share v AMYT looks pretty convincing this is amyt's issue. free stock charts from uk.advfn.com | currypasty | |
11/7/2016 13:37 | Divmad - In one interview it was suggested we would have a steady news flow starting in the summer (so about now). Other than partnerships, I cannot see what else there could be to report. | icebreaker | |
11/7/2016 11:58 | I suppose most PI AIM investors want near-term catalysts to drive share price levels higher. AMYT won't do that because it is in a waiting game mode now until their P3 trial process is a) ended, and b) given marketing approval. When will this be? What possible other catalysts for 2016 share price enhancement could there be? | divmad | |
11/7/2016 11:55 | The valuations were possibly about right based on readily available information regarding potential Markets and Trends in this Sector (see JPs Links above) and the Fund Raise was precisely what it was for the amount specified. The problem appears to relate to general Market sentiment towards AIM companies this year... the MMs appear to be very, very prudent in their valuation of AIM companies right now, valuing them based on their Assets, Cash in the Bank, known revenue streams and known operational costs... which is perhaps not a bad thing until lots of genuine, new Business is secured. | pottermagic2310 | |
11/7/2016 09:59 | Its just sellers every day, when will it turn ? You have to wonder if the original valuations, and fund raise were way out? | currypasty | |
10/7/2016 17:28 | hxxps://trademarks.j | jacksonpollack | |
10/7/2016 17:11 | hxxps://www.smi-onli | jacksonpollack | |
10/7/2016 16:59 | hxxp://www.strategyr | jacksonpollack | |
10/7/2016 16:56 | hxxp://www.fiercepha | jacksonpollack | |
08/7/2016 15:58 | Pap. Well at least you agree that all long term holders have been totally shafted in the laughable 8-1 consolidation share fiasco. Amazing the amount of pi's who say the sold out before the drop. There are many on all shares. | jacksonpollack | |
08/7/2016 14:24 | If I had his email address, I would. As with most bod's of aim companies, they don't like giving out details on how to contact them as 9 X out of 10 they'd be fending off disgruntled shareholders. Shocking the way the bod has left the share price to dwindle down 40% in a couple of months. But this is the casino, Wild West, circus, clown club called aim so anything goes and it's usually companies going bust. | jacksonpollack | |
08/7/2016 13:35 | JP, Why don't you email the CEO and ask where the €900,000 + revenue is appropriated? Buffy | buffythebuffoon | |
08/7/2016 10:31 | 24 to 14 come on BoD give us a break ! | currypasty | |
07/7/2016 17:48 | Bog standard news. Many bod members taking a wage but between the lot of them still nothing for shareholders apart from adding to their losses. Where is the revenue from Germany? | jacksonpollack |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions